{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:42:56Z","timestamp":1791074576786,"version":"4.1.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2002,10]]},"abstract":"<jats:p>\n            The antihypertrophic action of angiotensin (Ang)-converting enzyme (ACE) inhibitors in the heart is attributed in part to potentiation of bradykinin. Bradykinin prevents hypertrophy of cultured cardiomyocytes by releasing nitric oxide (NO) from endothelial cells, which increases cardiomyocyte guanosine 3\u20325\u2032-cyclic monophosphate (cyclic GMP). It is unknown whether cyclic GMP is essential for the action of bradykinin, or whether findings in isolated cardiomyocytes apply in whole hearts, in the presence of other cell types and mechanical\/dynamic activity. We now examine the contribution of cyclic GMP to the antihypertrophic action of bradykinin in cardiomyocytes and perfused hearts. In adult rat isolated cardiomyocytes cocultured with bovine aortic endothelial cells, the inhibitory action of bradykinin (10 \u03bcmol\/L) against Ang II (1 \u03bcmol\/L)\u2013induced [\n            <jats:sup>3<\/jats:sup>\n            H]phenylalanine incorporation was abolished by the soluble guanylyl cyclase inhibitor [1,2,4] oxadiazolo[4,3-a]quinoxalin-1-one (10 \u03bcmol\/L). In Langendorff-perfused rat hearts, Ang II (10 nmol\/L)\u2013induced increases in [\n            <jats:sup>3<\/jats:sup>\n            H]phenylalanine incorporation and atrial natriuretic peptide mRNA expression were prevented by bradykinin (100 nmol\/L), the NO donor sodium nitroprusside (3 \u03bcmol\/L), and the ACE inhibitor ramiprilat (100 nmol\/L). The acute antihypertrophic action of bradykinin was accompanied by increased left ventricular cyclic GMP, and the ramiprilat effect was attenuated by HOE 140 (1 \u03bcmol\/L, a B\n            <jats:sub>2<\/jats:sub>\n            -kinin receptor antagonist) or [1,2,4] oxadiazolo[4,3-a]quinoxalin-1-one (100 nmol\/L). In conclusion, bradykinin exerts a direct inhibitory action against the acute hypertrophic response to Ang II in rat isolated hearts, and elevation of cardiomyocyte cyclic GMP may be an important antihypertrophic mechanism used by bradykinin and ramiprilat in the heart.\n          <\/jats:p>","DOI":"10.1161\/01.hyp.0000032854.74042.cf","type":"journal-article","created":{"date-parts":[[2002,10,3]],"date-time":"2002-10-03T22:24:58Z","timestamp":1033683898000},"page":"498-503","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":30,"title":["Acute Antihypertrophic Actions of Bradykinin in the Rat Heart"],"prefix":"10.1161","volume":"40","author":[{"given":"Anke C.","family":"Rosenkranz","sequence":"first","affiliation":[{"name":"From the Howard Florey Institute, Parkville, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally G.","family":"Hood","sequence":"additional","affiliation":[{"name":"From the Howard Florey Institute, Parkville, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn L.","family":"Woods","sequence":"additional","affiliation":[{"name":"From the Howard Florey Institute, Parkville, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Dusting","sequence":"additional","affiliation":[{"name":"From the Howard Florey Institute, Parkville, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca H.","family":"Ritchie","sequence":"additional","affiliation":[{"name":"From the Howard Florey Institute, Parkville, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/5.2.95"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199008000-00012"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199322004-00002"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.100.23.2359"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.99-1010fje"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.1998.275.4.H1370"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1006\/jmcc.2000.1149"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119883"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001090050275"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.73.3.8348686"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.31.1.39"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.76.3.489"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.30.6.1348"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.23.6.919"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(98)00121-7"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1041230304"},{"key":"e_1_3_2_17_2","first-page":"H1493","volume":"264","year":"1993","unstructured":"Gr\u00e4fe M, Bossalier C, Graf K, Auch-Schwelk W, Baumgarten CR, Hildebrandt A, Fleck E. Effect of angiotensin-converting-enzyme inhibition on bradykinin metabolism by vascular endothelial cells. Am J Physiol. 1993; 264: H1493\u2013H1497.","journal-title":"Am J Physiol"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(00)02148-2"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.64.1.2909303"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.0000024106.81401.95"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1006\/abio.1999.4085"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(93)90697-Y"},{"key":"e_1_3_2_23_2","first-page":"S83","volume":"20","year":"1992","unstructured":"Linz W, Scholkens BA. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol. 1992; 20 (suppl 9): S83\u2013S90.","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(99)00070-3"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.31.5.1104"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.35.1.19"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.18.12.6983"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117729"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03257240"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.1999.277.2.H818"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199503000-00014"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702233"},{"key":"e_1_3_2_33_2","first-page":"49","volume":"144","year":"1999","unstructured":"Heller R, Polack T, Grabner R, Till U. Nitric oxide inhibits proliferation of human endothelial cells via a mechanism independent of cGMP. Atherosclerosis. 1999; 144: 49\u201357.","journal-title":"Atherosclerosis"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.2001.280.5.H2350"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/368850a0"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.25.6.1306"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1995.268.2.C366"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00005366"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.85.6.534"},{"key":"e_1_3_2_40_2","first-page":"2416","volume":"85","year":"2000","unstructured":"Piatti PM, Monti LD, Zavaroni I, Valsecchi G, Van Phan C, Costa S, Conti M, Sandoli EP, Solerte B, Pozza G, Pontiroli AE, Reaven G. Alterations in nitric oxide\/cyclic-GMP pathway in nondiabetic siblings of patients with type 2 diabetes. J Clin Endocrinol Metab. 2000; 85: 2416\u20132420.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.HYP.0000032854.74042.CF","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T16:17:43Z","timestamp":1715530663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.HYP.0000032854.74042.CF"}},"subtitle":["Importance of Cyclic GMP"],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["10.1161\/01.HYP.0000032854.74042.CF"],"URL":"https:\/\/doi.org\/10.1161\/01.hyp.0000032854.74042.cf","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]},"assertion":[{"value":"2002-06-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-07-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-08-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}